EMEA-002665-PIP02-20
Key facts
Active substance |
Loncastuximab tesirine
|
Therapeutic area |
Oncology
|
Decision number |
P/0400/2021
|
PIP number |
EMEA-002665-PIP02-20
|
Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
Condition(s) / indication(s) |
Treatment of mature B-cell neoplasms
|
Route(s) of administration |
Intravenous use
|
Contact for public enquiries |
Swedish Oprhan Biovitrum AB (publ)
Email: info@sobi.com |
Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|